Cargando…
Research status on immunotherapy trials of gastric cancer
The breakthrough of immune checkpoint inhibitor (ICI) therapy has created extensive opportunities for cancer immunotherapy. Especially, the block of programmed death-1/programmed death ligand 1 (PD-L1) axis using ICIs has become a new therapeutic strategy to treat advanced gastric cancer (GC). Howev...
Autores principales: | Liang, Chao, Wu, Heng-Miao, Yu, Wei-Ming, Chen, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316931/ https://www.ncbi.nlm.nih.gov/pubmed/34368297 http://dx.doi.org/10.12998/wjcc.v9.i21.5782 |
Ejemplares similares
-
Immunotherapy for advanced gastric cancer
por: Leowattana, Wattana, et al.
Publicado: (2023) -
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
por: Mandlik, Deepa S, et al.
Publicado: (2023) -
Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
por: Yan, Cong, et al.
Publicado: (2019) -
Progress in the research of cuproptosis and possible targets for cancer therapy
por: Wang, Jiang, et al.
Publicado: (2023) -
Evaluation of polygenic risk score for risk prediction of gastric cancer
por: Wang, Xiao-Yu, et al.
Publicado: (2023)